FDA recently issued a draft guidance: “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” It’s aiming at drug manufacturing sites regulated by CDER/CBER/CVM and lays out what FDA expects when a company chooses to submit a written response to an FDA 483.

Core Message: Treat your 483 Response like a Quality-system Artifact

FDA makes it clear that if you submit a written response, it may be a primary or key component of FDA’s review. Responses should be accurate, clear, concise, and well-organized, and not vague promises.

The “15 Business Day” Clock

FDA recommends responding within 15 business days of the 483 being issued (and if the 483 is amended, the clock restarts from the amendment). FDA also notes it will not ordinarily delay regulatory action (including a Warning Letter) to review late responses.

FDA also is urging a single consolidated response addressing all observations. If issues are complex and cannot be fully remediated within the window, FDA still expects a CAPA plan and timeline within those 15 business days.

What FDA Says to Include (Minimum Elements)

FDA recommends structuring your response with a table of contents and including, at minimum:

• Establishment identification (including FEI)
• A copy of the issued FDA 483
• Who prepared the response (and relationship if external)
• A signatory with executive authority to commit resources (often site leadership / executive management)
• Include authorization documentation when any third party is involved.
• Any relevant global investigation plans/reports (if applicable)
• An executive summary plus an observation-by-observation remediation package with attachments

The Quality Themes FDA is Emphasizing

Risk framing: Companies must address potential impact to patients and products, evaluate any distributed product still within expiry, and determine whether quality may be affected.
Investigation rigor: Responses should show scope, impacted lots/products, root cause(s), and whether issues are systemic, not a narrow “single event” write-up. 
CAPA effectiveness: FDA highlights the need for interim controls, timelines, deliverables, and effectiveness evaluation, and states that weak effectiveness should trigger reassessment of the investigation and CAPA. 
Management owns accountability: Leadership must understand the observations, assess risk, and make sure corrective actions happen, and the establishment remains responsible for CGMP compliance even when consultants are involved.

A Practical “15-day” Approach

1. Day 0–2: Assign an executive owner/signatory and build a cross-functional investigation team.
2. Day 2–7: Define scope, begin risk assessment, document interim controls, and draft investigation/CAPA plans.
3. Day 7–15: Write a consolidated response with evidence, attachments, clear timelines, and an effectiveness plan.

Bottom line: FDA is standardizing what a “credible” 483 response looks like: structured, risk-based, management-owned, and backed by investigation depth and CAPA effectiveness – not just commitments.

If you need an extra set of hands to help, please feel free to contact us now.